Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765

December 5, 2010 By Bio-Medicine.Org

ORLANDO, Fla. and SUNNYVALE, Calif., Dec. 5, 2010
/PRNewswire-FirstCall/ — Pharmacyclics, Inc. (Nasdaq:
PCYC
) today announced data from three Chronic Lymphocytic
Leukemia (CLL) presentations at the American Society of Hematology
(ASH) Annual Meeting describing the Btk-selective inhibitor
PCI-32765.  Two presentations report preclinical data, and one
presentation reports clinical data from a pooled analysis of 54
patients with CLL or Small Lymphocytic Lymphoma (SLL) treated with
PCI-32765.

The two preclinical abstracts focus on the mechanism of action
of this novel drug.  An oral presentation titled “Bruton’s
Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR and Nurselike
Cell-Derived Activation of CLL Cells In Vitro and In Vivo”
is being presented by Sabine Ponader, PhD from the MD Anderson
Cancer Center.  The other preclinical presentation is a poster
presented by Sarah Herman, PhD of the laboratory of John Byrd, MD,
of The Ohio State University titled “The Kinase Inhibitor,
PCI-32765, Demonstrates Activity in Chronic Lymphocytic Leukemia
Cells Independent of Microenvironmental Survival Signals.” Data
from these two presentations together suggest a model whereby
PCI-32765 directly affects CLL cells by inducing apoptosis, and
also blocks the ability of CLL cells to migrate to and to adhere to
lymph nodes, a protective environment where the tumors grow. The
clinical results of treatment, as discussed below, appear to bear
out these combined mechanisms, with evidence of impairment of both
homing to lymph nodes and cell viability in the typical clinical
response to PCI-32765.

Data Results from the Pooled Phase IA and IB Studies in
CLL/SLLThe oral presentation, titled “The Bruton’s Tyrosine Kinase
Inhibitor PCI-32765 is Well Tolerated and Demonstrates Promising
Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small
Lymphocytic Lymphom

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech